In a fast-changing pharmaceutical sector, Laprophan continues its development with a clear ambition: strengthening its Moroccan roots while expanding its international presence.
Under the leadership of its President, Dr. Farid Bennis, the Group is entering a new strategic phase through its development in Europe, notably with Rivopharm, a Swiss pharmaceutical company recognized for its industrial, regulatory, and scientific expertise.
This momentum marks an important turning point in Laprophan’s history. It reflects the ambition to build a strong pharmaceutical group capable of connecting Moroccan industrial excellence with the highest international standards.
As a pharmacist, industrial leader, and visionary, Dr. Farid Bennis embodies a journey shaped by rigor, innovation, and commitment to healthcare. His path reflects a strong conviction: Morocco has the talent and capabilities required to play a major role in the global pharmaceutical value chain.
Through this new step, Laprophan strengthens its key pillars: quality, innovation, treatment accessibility, industrial development, and international openness.
More than a geographic expansion, this milestone illustrates a vision: growing a national champion, rooted in Morocco and open to the world.
Faithful to its public health mission, Laprophan reaffirms its purpose: to build, from Morocco, a leading pharmaceutical player, sustainable, ambitious, and future-oriented.